Drug Information

Drug General Information
Drug ID
D01UBX
Former ID
DAP001342
Drug Name
Aclarubicin
Synonyms
Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A
Drug Type
Small molecular drug
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Approved [536361], [551871]
Therapeutic Class
Anticancer Agents
Structure
Download
2D MOL

3D MOL
Formula
C42H53NO15
Canonical SMILES
CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C<br />4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C<br />)C)O
InChI
1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19+,20+,24+,27+,28+,29+,30+,31+,35+,39-,40-,42-/m1/s1
InChIKey
USZYSDMBJDPRIF-IFRWQTOUSA-N
CAS Number
CAS 57576-44-0
PubChem Compound ID
152688
PubChem Substance ID
46229071, 49994960, 50296684, 104434334, 135109304
SuperDrug ATC ID
L01DB04
SuperDrug CAS ID
cas=057576440
Target and Pathway
Target(s) DNA topoisomerase II Target Info Inhibitor [534989], [535576]
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 5349891,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34.
Ref 535576Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.